{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01547897: Phase 2 Interventional Completed Type 2 Diabetes Mellitus
(2012)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00042081: Phase 3 Interventional Completed Coronary Artery Disease
(2002)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00306904: Phase 2 Interventional Completed Diabetic Macular Edema
(2006)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT02947867: Phase 2/Phase 3 Interventional Unknown status Ischaemic Central Retinal Vein Occlusion
(2017)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
USAN:ETAFILCON A [USAN]
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
Eur J Anaesthesiol. Dec 2014;31(12):663-8.: Not Applicable Human clinical trial Completed N/A
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
INN:limaresiquimod [INN]
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
USAN:LOTRAFILCON B [USAN]
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
USAN:LOTRAFILCON A [USAN]
Source URL:
Class:
POLYMER
